ストックスクリーナーアプリを入手
2.15
0.46%
-0.01
前日終値:
$2.16
開ける：
$2.18
24時間の取引高:
24,657
Relative Volume:
0.68
時価総額：
$23.08M
収益：
$56.60M
当期純損益:
$-34.12M
株価収益率:
-0.469
EPS:
-4.5844
ネットキャッシュフロー:
$-1.36M
1週間 パフォーマンス:
-4.44%
1か月 パフォーマンス:
+2.14%
6か月 パフォーマンス:
-19.17%
1年 パフォーマンス:
-9.66%
1日の値動き範囲:
$2.12
$2.18
1週間の範囲:
$2.12
$2.25
52週間の値動き範囲:
$1.6501
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Compare AYTU vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.15 | 23.18M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | 開始されました | Lake Street | Buy |
| 2025-06-30 | 開始されました | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 開始されました | H.C. Wainwright | Buy |
Aytu Biopharma Inc (AYTU) 最新ニュース
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsBollinger Walk - DonanımHaber
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic ReviewEarnings Beat Streak - dars.gov.et
Aytu BioPharma Holds Steady Near $2.16 Amid Modest Gains – Key Levels in FocusFactor Valuation - DonanımHaber
Aytu BioPharma | SCHEDULE 13G/A: Others - Moomoo
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. Actuals & Estimates (NASDAQ:AYTU) - TradingView
AYTU Forecast — Price Target — Prediction for 2027 - TradingView
Aytu BioPharma, Inc. Actuals & Estimates (LSE:0A8M) - TradingView
0A8M Forecast — Price Target — Prediction for 2027 - TradingView
Aytu Biopharmato Continue Selling Existing - Moomoo
Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
Aytu BioPharma (AYTU) ends Metadate CD license agreement with Lannett - Stock Titan
Price to sales forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to EBIT forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to revenue forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
AYTU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aytu Biopharma Inc (AYTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Institutional Confidence - TradingKey
Aytu Biopharma Inc (AYTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AYTU: EXXUA's unique profile and RxConnect network drive strong early growth and market resilience - TradingView
AYTU: EXXUA’s unique profile and RxConnect network drive growth and resilience amid market shifts - TradingView
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aytu BioPharma (AYTU) Surges 4.2% as Shares Approach Resistance at $2.28Shakeout Pattern - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 4.23% as Shares Test Key Resistance at $2.28PCR Spike - newsline.com
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AYTU Q1 2026 Earnings: EPS Misses Estimates by 1.88%, Shares Decline 5.45%Forward Guidance Trends - dars.gov.et
Aytu BioPharma (AYTU) Slips 1.83% as Stock Tests Key Support Near $2.04WMA Signal - newsline.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AYTU Maintained by Ascendiant Capital -- Price Target Raised to $14.50 - GuruFocus
AYTU Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterUpward Estimate Revision - newsline.com
Aytu BioPharma Gains 5.89% as Small-Cap Biotech Finds TractionDaily Profile - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 3.3% as Shares Approach Resistance at $2.30Channel Breakout - newsline.com
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 - Hastings Tribune
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance ZoneSector ETF Flow - The Legal Advocate
AYTUAytu BioPharma Inc Stock Price and Quote - Finviz
AYTU Q1 2026 Earnings: Narrow EPS Miss Amid Limited Revenue Disclosure; Shares Edge HigherNet Income Trends - newsline.com
AYTU Q1 2026 Earnings: EPS Misses Estimates by 1.88%, Stock Declines Amid Sparse DisclosureReturn On Assets - The Legal Advocate
AYTU: EXXUA’s launch drives growth as legacy ADHD revenues decline, with strong financial footing - TradingView
AYTU Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesEarnings Trend Analysis - The Legal Advocate
AYTU Q1 2026 Earnings EPS Misses Estimates Amidst Operational ChallengesThe Legal Advocate - The Legal Advocate
Aytu BioPharma (AYTU) Holds Near Support Amid Low-Volume TradingWeak Sell Signals - newsline.com
Aytu BioPharma Rallies as Shares Test Key Resistance LevelsCumulative Volume - The Legal Advocate
Aytu BioPharma Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock MovementEarnings Call Highlights - The Legal Advocate
AYTU Q1 2026 Earnings: EPS Misses Estimates Amid Operational Challenges, Stock Rises SlightlyCFO Commentary Report - newsline.com
Aytu BioPharma Gains 1.64% as Stock Tests Key Resistance at $2.28ETF Flow - thelegaladvocate.com
AYTU Stock Slips Before Exxua Update Investors Are Watching - Bez Kabli
Aytu Biopharma Inc (AYTU) 財務データ
収益
当期純利益
現金流量
EPS
1.50%
0.79%
大文字化:
|
ボリューム (24 時間):